{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Saline+solution+for+injection&page=2",
    "query": {
      "intervention": "Saline solution for injection",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Saline+solution+for+injection&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-26T03:56:35.962Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01637376",
      "title": "Photodynamic Therapy (PDT) With Temoporfin for Non-Resectable Non-Small-Cell Lung Cancer",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell-Lung"
      ],
      "interventions": [
        {
          "name": "Temoporfin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Arkansas",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2012-07",
      "completion_date": "2014-01",
      "has_results": false,
      "last_update_posted_date": "2014-01-15",
      "last_synced_at": "2026-09-26T03:56:35.962Z",
      "location_count": 1,
      "location_summary": "Little Rock, Arkansas",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01637376"
    },
    {
      "nct_id": "NCT02112097",
      "title": "ASIS for Enbrel in Plaque Psoriasis",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Plaque Psoriasis."
      ],
      "interventions": [
        {
          "name": "Gadolinium",
          "type": "DRUG"
        },
        {
          "name": "Efficacy of Enbrel subcutaneously at Week 12",
          "type": "DRUG"
        },
        {
          "name": "Efficacy of Enbrel subcutaneously at Week 24",
          "type": "DRUG"
        },
        {
          "name": "Efficacy of Enbrel subcutaneously at Week 36",
          "type": "DRUG"
        },
        {
          "name": "Efficacy of Enbrel subdermally at Week 12",
          "type": "DRUG"
        },
        {
          "name": "Efficacy of Enbrel subdermally at Week 24",
          "type": "DRUG"
        },
        {
          "name": "Efficacy of Enbrel subdermally at Week 36",
          "type": "DRUG"
        },
        {
          "name": "PASI 75 n(%) subcutaneously at Week 12",
          "type": "DRUG"
        },
        {
          "name": "PASI 75 n(%) subcutaneously at Week 24",
          "type": "DRUG"
        },
        {
          "name": "PASI 75 n(%) subcutaneously at Week 36",
          "type": "DRUG"
        },
        {
          "name": "PASI 75 n(%) subdermally at Week 12",
          "type": "DRUG"
        },
        {
          "name": "PASI 75 n(%) subdermally at Week 24",
          "type": "DRUG"
        },
        {
          "name": "PASI 75 n(%) subdermally at Week 36",
          "type": "DRUG"
        },
        {
          "name": "Adverse Reactions of Enbrel subcutaneously",
          "type": "DRUG"
        },
        {
          "name": "Adverse Reactions of Enbrel subdermally at Week 36",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ASIS Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "21 Years to 65 Years"
      },
      "enrollment_count": 60,
      "start_date": "2016-01",
      "completion_date": "2017-06",
      "has_results": false,
      "last_update_posted_date": "2015-06-24",
      "last_synced_at": "2026-09-26T03:56:35.962Z",
      "location_count": 1,
      "location_summary": "Westminster, California",
      "locations": [
        {
          "city": "Westminster",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02112097"
    },
    {
      "nct_id": "NCT05328726",
      "title": "Single, Ascending Dose, First Time in Human Study for GZR18 in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "GZR-18",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Gan and Lee Pharmaceuticals, USA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "MALE",
        "summary": "18 Years to 60 Years · Male only"
      },
      "enrollment_count": 24,
      "start_date": "2022-03-08",
      "completion_date": "2023-03-09",
      "has_results": false,
      "last_update_posted_date": "2023-03-23",
      "last_synced_at": "2026-09-26T03:56:35.962Z",
      "location_count": 1,
      "location_summary": "Lincoln, Nebraska",
      "locations": [
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05328726"
    },
    {
      "nct_id": "NCT00822978",
      "title": "Phase 1 Study for Safety of ACHN-490",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "ACHN-490 Injection vs placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Achaogen, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 39,
      "start_date": "2009-01",
      "completion_date": "2009-10",
      "has_results": false,
      "last_update_posted_date": "2012-02-27",
      "last_synced_at": "2026-09-26T03:56:35.962Z",
      "location_count": 1,
      "location_summary": "Kalamazoo, Michigan",
      "locations": [
        {
          "city": "Kalamazoo",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00822978"
    },
    {
      "nct_id": "NCT04121780",
      "title": "Growth Hormone Replacement Therapy for Retried Professional Football Players",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "TBI (Traumatic Brain Injury)",
        "Concussion, Brain",
        "Sport Injury",
        "Anterior Pituitary Hyposecretion Syndrome",
        "Hypopituitarism",
        "Growth Hormone Deficiency"
      ],
      "interventions": [
        {
          "name": "Growth Hormone",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Center for Neurological Studies",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "76 Years",
        "sex": "MALE",
        "summary": "18 Years to 76 Years · Male only"
      },
      "enrollment_count": 42,
      "start_date": "2019-10-08",
      "completion_date": "2026-09",
      "has_results": false,
      "last_update_posted_date": "2023-02-08",
      "last_synced_at": "2026-09-26T03:56:35.962Z",
      "location_count": 1,
      "location_summary": "Dearborn, Michigan",
      "locations": [
        {
          "city": "Dearborn",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04121780"
    },
    {
      "nct_id": "NCT03086343",
      "title": "A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Rheumatoid Arthritis (RA)"
      ],
      "interventions": [
        {
          "name": "Abatacept",
          "type": "DRUG"
        },
        {
          "name": "Placebo for abatacept (0.9% Sodium Chloride Injection or Solution for Infusion)",
          "type": "DRUG"
        },
        {
          "name": "Upadacitinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo for upadacitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 657,
      "start_date": "2017-05-09",
      "completion_date": "2023-06-06",
      "has_results": true,
      "last_update_posted_date": "2024-07-18",
      "last_synced_at": "2026-09-26T03:56:35.962Z",
      "location_count": 44,
      "location_summary": "Peoria, Arizona • Sun City, Arizona • Tucson, Arizona + 40 more",
      "locations": [
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Fullerton",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03086343"
    },
    {
      "nct_id": "NCT00995917",
      "title": "A Pilot Study of Acupoint Injection for Primary Dysmenorrhea",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Dysmenorrhea",
        "Pain, Menstrual"
      ],
      "interventions": [
        {
          "name": "Vitamin K acupoint injection",
          "type": "OTHER"
        },
        {
          "name": "Saline Injection",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "25 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 25 Years · Female only"
      },
      "enrollment_count": 18,
      "start_date": "2009-10",
      "completion_date": "2011-07",
      "has_results": false,
      "last_update_posted_date": "2012-04-20",
      "last_synced_at": "2026-09-26T03:56:35.962Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00995917"
    },
    {
      "nct_id": "NCT00656890",
      "title": "A Study of MDX-1100 in Subjects With Active Ulcerative Colitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ulcerative Colitis"
      ],
      "interventions": [
        {
          "name": "sterile saline for injection",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MDX-1100",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 110,
      "start_date": "2008-04",
      "completion_date": "2009-09",
      "has_results": false,
      "last_update_posted_date": "2015-10-12",
      "last_synced_at": "2026-09-26T03:56:35.962Z",
      "location_count": 7,
      "location_summary": "Port Orange, Florida • Tampa, Florida • Chicago, Illinois + 4 more",
      "locations": [
        {
          "city": "Port Orange",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chevy Chase",
          "state": "Maryland"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00656890"
    },
    {
      "nct_id": "NCT04540913",
      "title": "RHA® 3 Versus Restylane-L® for Lip Augmentation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [],
      "conditions": [
        "Lip Augmentation",
        "Lip"
      ],
      "interventions": [
        {
          "name": "RHA 3",
          "type": "DEVICE"
        },
        {
          "name": "Restylane-L",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Teoxane SA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "22 Years and older"
      },
      "enrollment_count": 202,
      "start_date": "2020-10-22",
      "completion_date": "2022-09-07",
      "has_results": true,
      "last_update_posted_date": "2025-02-03",
      "last_synced_at": "2026-09-26T03:56:35.962Z",
      "location_count": 1,
      "location_summary": "Bradenton, Florida",
      "locations": [
        {
          "city": "Bradenton",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04540913"
    },
    {
      "nct_id": "NCT00454818",
      "title": "Efficacy and Safety Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Heart Failure, Congestive",
        "Dilated Cardiomyopathy"
      ],
      "interventions": [
        {
          "name": "MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study)",
          "type": "GENETIC"
        },
        {
          "name": "Placebo Infusion",
          "type": "PROCEDURE"
        },
        {
          "name": "MYDICAR Phase 2 (Placebo-controlled, Randomized Study)",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "PROCEDURE"
      ],
      "sponsor": "Celladon Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 51,
      "start_date": "2007-03",
      "completion_date": "2012-08",
      "has_results": true,
      "last_update_posted_date": "2014-08-20",
      "last_synced_at": "2026-09-26T03:56:35.962Z",
      "location_count": 22,
      "location_summary": "San Diego, California • Gainesville, Florida • Chicago, Illinois + 15 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00454818"
    }
  ]
}